NCT04594941View on ClinicalTrials.gov

A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

May 26, 2022

Study Completion Date

May 26, 2022

Conditions
Coronary Artery Disease (CAD)Ischemic Heart Disease
Interventions
DRUG

Flurpiridaz (18F) Injection

All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.

Trial Locations (5)

33012

Indago Research and Health Center, Hialeah

33155

Pioneer Clinical Studies, Miami

33169

Amavita Clinical Research, LLC, North Miami Beach

39720

University of Tennessee Medical Center, Knoxville

77493

Memorial City and Katy Cardiology Associates, Katy

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
lead

GE Healthcare

INDUSTRY

NCT04594941 - A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes | Biotech Hunter | Biotech Hunter